LEADER 01720nam  2200385z- 450 
001 9910261132103321
005 20231214133235.0
035   $a(CKB)4100000002484765
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/55224
035   $a(EXLCZ)994100000002484765
100   $a20202102d2017      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aOncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
210   $cFrontiers Media SA$d2017
215   $a1 electronic resource (193 p.)
225 1 $aFrontiers Research Topics
311   $a2-88945-358-8 
330   $aThe ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.
610   $atheranostic nanomedicine
610   $acancer immunotherapy
610   $aoncolytic viruses
610   $aantitumor immunity
610   $aoncoimmunology
610   $agene expression
610   $atransgenes
700   $aBenjamin Gesundheit$4auth$01278230
702   $aJoshua P. Rosenzweig$4auth
906   $aBOOK
912   $a9910261132103321
996   $aOncolytic Viruses - Genetically Engineering the Future of Cancer Therapy$93034281
997   $aUNINA